Hoyland; excellent points.Another reason is the general and very...

Hoyland; excellent points.

Another reason is the general and very strong increase in RNAi interest in the US where many RNAi companies have already doubled or tripled in recent times. Imagine being a biotech investor in the US following the field and the explosive share price growth in Arrowhead, Tekmira and Alnylam. Then you find out about an obscure Australian RNAi company at very low market capitalisation. As you go deeper and realise just what a gem it is, and that clinical trial data is just around the corner, and that it is a platform company that just might actually be more valuable than the rest of the RNAi space put together; well, I can understand the excitement!

Us long termers got excited years ago, now the very first few risk taking US investors are getting excited. What I'm looking forward to is when the mob gets excited! If this coincides with some good data coming out, who knows where this could go. A biotech Poseidon?